Thomas Hughes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Hughes has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Benedict Daniel Michael
The Brain Infection and Inflammation Group, Liverpool Interdisciplinary Neuroscience Centre (LINC), Clinical Infection, Microbiology, and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
2 shared publications - Adjanie Patabendige
Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
1 shared publication - Ajai K. Malhotra
Surgery, University of Vermont Medical Center, Burlington, Vermont, USA
1 shared publication - Ajan Subramanian
Department of Computer Science, University of California, Irvine, Irvine, CA, United States
1 shared publication - Alberto Vogrig
Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; Department of Medicine (DMED), University of Udine, Udine, Italy
1 shared publication - Alex K. Pearce
Health Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication
Latest Publications
- Open Access
International evaluation of the SEIZUre Risk in Encephalitis (SEIZURE) score for predicting acute seizure risk
Objective: Encephalitis is brain parenchyma inflammation, frequently resulting in seizures which worsens outcomes. Early anti-seizure medication could improve outcomes but requires identifying patients at greatest risk of acute seizures. The SEIZURE (SEIZUre Risk in Encephalitis) score was developed in UK cohorts to stratify patients by acute seizure risk. A ‘basic score’ used Glasgow Coma Scale (GCS), fever and age; the ‘advanced score’ added aetiology. This study aimed to evaluate the score internationally to determine its global applicability. Design: Patients were retrospectively analysed regionally, and by country, in this international evaluation study. Univariate analysis was conducted between patients who did and did not have inpatient seizures, followed by multivariable logistic regression, hierarchical clustering and analysis of the area under the receiver operating curves (AUROC) with 95% CIs. Participants and setting: 2032 patients across 13 countries were identified, among whom 1324 were included in SEIZURE score calculations and 970 were included in regression modelling. The involved countries comprised 19 organisations spanning all WHO regions. Outcome measures: The primary outcome was measuring inpatient seizure rates. Results: Autoantibody-associated encephalitis, low GCS and presenting with a seizure were frequently associated with inpatient seizures; fever showed no association. Globally, the score had limited discriminatory ability (basic AUROC 0.58 (95% CI 0.55 to 0.62), advanced AUROC 0.63 (95% CI 0.60 to 0.66)). The scoring system performed acceptably in western Europe, excluding Spain, with the best performance in Portugal (basic AUROC 0.82 (95% CI 0.69 to 0.94), advanced AUROC 0.83 (95% CI 0.72 to 0.95)). Conclusions: The SEIZURE score performed best in several countries in Western Europe but performed poorly elsewhere, partly due to differing and unknown aetiologies. In most regions, the score did not reach a threshold to be clinically useful. The Western European results could aid in designing clinical trials assessing primary anti-seizure prophylaxis in encephalitis following further prospective trials. Beyond Western Europe, there is a need for tailored, localised scoring systems and future large-scale prospective studies with optimised aetiological testing to accurately identify high-risk patients.
Open AccessInternational evaluation of the SEIZUre Risk in Encephalitis (SEIZURE) score for predicting acute seizure risk
Objective: Encephalitis is brain parenchyma inflammation, frequently resulting in seizures which worsens outcomes. Early anti-seizure medication could improve outcomes but requires identifying patients at greatest risk of acute seizures. The SEIZURE (SEIZUre Risk in Encephalitis) score was developed in UK cohorts to stratify patients by acute seizure risk. A ‘basic score’ used Glasgow Coma Scale (GCS), fever and age; the ‘advanced score’ added aetiology. This study aimed to evaluate the score internationally to determine its global applicability. Design: Patients were retrospectively analysed regionally, and by country, in this international evaluation study. Univariate analysis was conducted between patients who did and did not have inpatient seizures, followed by multivariable logistic regression, hierarchical clustering and analysis of the area under the receiver operating curves (AUROC) with 95% CIs. Participants and setting: 2032 patients across 13 countries were identified, among whom 1324 were included in SEIZURE score calculations and 970 were included in regression modelling. The involved countries comprised 19 organisations spanning all WHO regions. Outcome measures: The primary outcome was measuring inpatient seizure rates. Results: Autoantibody-associated encephalitis, low GCS and presenting with a seizure were frequently associated with inpatient seizures; fever showed no association. Globally, the score had limited discriminatory ability (basic AUROC 0.58 (95% CI 0.55 to 0.62), advanced AUROC 0.63 (95% CI 0.60 to 0.66)). The scoring system performed acceptably in western Europe, excluding Spain, with the best performance in Portugal (basic AUROC 0.82 (95% CI 0.69 to 0.94), advanced AUROC 0.83 (95% CI 0.72 to 0.95)). Conclusions: The SEIZURE score performed best in several countries in Western Europe but performed poorly elsewhere, partly due to differing and unknown aetiologies. In most regions, the score did not reach a threshold to be clinically useful. The Western European results could aid in designing clinical trials assessing primary anti-seizure prophylaxis in encephalitis following further prospective trials. Beyond Western Europe, there is a need for tailored, localised scoring systems and future large-scale prospective studies with optimised aetiological testing to accurately identify high-risk patients.
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , 1273-1282
Viral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies
The blood-brain barrier (BBB) protects the brain from pathogenic microorganisms. Neurologic complications from viral infections, including herpes simplex virus, varicella zoster virus, HIV, Japanese encephalitis virus, and SARS-CoV-2, are linked to BBB dysfunction and loss of barrier integrity. Increased BBB permeability associated with viral infections can occur through several mechanisms, such as direct neurotropism, Trojan horse mechanisms, or systemic infection and inflammation. Viruses cause direct and indirect immune-mediated damage. Understanding these neuroimmune mechanisms is critical to establish therapeutic strategies to protect BBB function. This review describes the effect of viral infection on the BBB, clinical methods to assess BBB integrity, and clinical management approaches to address viral-induced BBB damage.
- 29 September 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , 1273-1282
Open AccessViral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies
The blood-brain barrier (BBB) protects the brain from pathogenic microorganisms. Neurologic complications from viral infections, including herpes simplex virus, varicella zoster virus, HIV, Japanese encephalitis virus, and SARS-CoV-2, are linked to BBB dysfunction and loss of barrier integrity. Increased BBB permeability associated with viral infections can occur through several mechanisms, such as direct neurotropism, Trojan horse mechanisms, or systemic infection and inflammation. Viruses cause direct and indirect immune-mediated damage. Understanding these neuroimmune mechanisms is critical to establish therapeutic strategies to protect BBB function. This review describes the effect of viral infection on the BBB, clinical methods to assess BBB integrity, and clinical management approaches to address viral-induced BBB damage.
- 7 July 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (7) , e261786
Recurrent respiratory papillomatosis causing critical airway obstruction in the third trimester of pregnancy
Recurrent respiratory papillomatosis (RRP) is a rare complication of human papillomavirus infection, resulting in exophytic growths into the respiratory tract. A primigravida patient with RRP presented with increasing stridor at 32 weeks of gestation. The patient required emergency surgery at a tertiary head and neck centre, with a standby obstetric and neonatal team available, and later went on to have a normal term delivery. RRP in pregnancy carries a high risk of airway compromise and requires a multidisciplinary approach to manage the condition. Hospitals should have local guidelines on the location for non-obstetric surgery during pregnancy.
- 7 July 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (7) , e261786
Recurrent respiratory papillomatosis causing critical airway obstruction in the third trimester of pregnancy
Recurrent respiratory papillomatosis (RRP) is a rare complication of human papillomavirus infection, resulting in exophytic growths into the respiratory tract. A primigravida patient with RRP presented with increasing stridor at 32 weeks of gestation. The patient required emergency surgery at a tertiary head and neck centre, with a standby obstetric and neonatal team available, and later went on to have a normal term delivery. RRP in pregnancy carries a high risk of airway compromise and requires a multidisciplinary approach to manage the condition. Hospitals should have local guidelines on the location for non-obstetric surgery during pregnancy.
- Open Access
- 6 September 2024
- Published by Elsevier in Future Healthcare Journal
- Vol. 11 (4) , 100173
The physician's role in mitigating the climate crisis
- 6 September 2024
- Published by Elsevier in Future Healthcare Journal
- Vol. 11 (4) , 100173
Open AccessThe physician's role in mitigating the climate crisis
- Open Access
- 8 December 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (8) , 1787-1795
A clinical approach to the investigation and management of long COVID associated neuropathic pain
COVID–19 has been associated with a wide range of ongoing symptoms following recovery from the acute SARS-CoV-2 infection. Around one in three people with COVID-19 develop neurological symptoms with many reporting neuropathic pain and associated symptoms, including paraesthesia, numbness, and dysesthesia. Whilst the pathophysiology of long COVID-19-associated neuropathic pain remains unclear, it is likely to be multifactorial. Early identification, exclusion of common alternative causes, and a biopsychosocial approach to the management of the symptoms can help in relieving the burden of disease and improving the quality of life for patients.
- 8 December 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (8) , 1787-1795
Open AccessA clinical approach to the investigation and management of long COVID associated neuropathic pain
COVID–19 has been associated with a wide range of ongoing symptoms following recovery from the acute SARS-CoV-2 infection. Around one in three people with COVID-19 develop neurological symptoms with many reporting neuropathic pain and associated symptoms, including paraesthesia, numbness, and dysesthesia. Whilst the pathophysiology of long COVID-19-associated neuropathic pain remains unclear, it is likely to be multifactorial. Early identification, exclusion of common alternative causes, and a biopsychosocial approach to the management of the symptoms can help in relieving the burden of disease and improving the quality of life for patients.